SCWORX CORP (WORX) Fundamental Analysis & Valuation
NASDAQ:WORX • US78396V2088
Current stock price
1.06 USD
-0.47 (-30.72%)
At close:
0.9549 USD
-0.11 (-9.92%)
After Hours:
This WORX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. WORX Profitability Analysis
1.1 Basic Checks
- In the past year WORX has reported negative net income.
- WORX had a negative operating cash flow in the past year.
- In the past 5 years WORX always reported negative net income.
- In the past 5 years WORX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -56.28%, WORX is not doing good in the industry: 82.86% of the companies in the same industry are doing better.
- WORX's Return On Equity of -62.13% is on the low side compared to the rest of the industry. WORX is outperformed by 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.28% | ||
| ROE | -62.13% | ||
| ROIC | N/A |
ROA(3y)-45.87%
ROA(5y)-39.87%
ROE(3y)-63.58%
ROE(5y)-55.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of WORX (31.96%) is worse than 77.14% of its industry peers.
- WORX's Gross Margin has been stable in the last couple of years.
- WORX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.89%
GM growth 5Y-0.41%
2. WORX Health Analysis
2.1 Basic Checks
- WORX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, WORX has more shares outstanding
- Compared to 5 years ago, WORX has more shares outstanding
- The debt/assets ratio for WORX has been reduced compared to a year ago.
2.2 Solvency
- WORX has an Altman-Z score of -5.21. This is a bad value and indicates that WORX is not financially healthy and even has some risk of bankruptcy.
- WORX has a worse Altman-Z score (-5.21) than 77.14% of its industry peers.
- WORX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.21 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- A Current Ratio of 2.72 indicates that WORX has no problem at all paying its short term obligations.
- With a decent Current ratio value of 2.72, WORX is doing good in the industry, outperforming 62.86% of the companies in the same industry.
- A Quick Ratio of 2.72 indicates that WORX has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 2.72, WORX is doing good in the industry, outperforming 65.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.72 |
3. WORX Growth Analysis
3.1 Past
- WORX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1192.80%.
- Looking at the last year, WORX shows a decrease in Revenue. The Revenue has decreased by -3.75% in the last year.
- WORX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.19% yearly.
EPS 1Y (TTM)-1192.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.3%
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-10.69%
Revenue growth 5Y-11.19%
Sales Q2Q%13.78%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. WORX Valuation Analysis
4.1 Price/Earnings Ratio
- WORX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. WORX Dividend Analysis
5.1 Amount
- No dividends for WORX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
WORX Fundamentals: All Metrics, Ratios and Statistics
1.06
-0.47 (-30.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)03-31 2026-03-31
Earnings (Next)05-13 2026-05-13
Inst Owners2.98%
Inst Owner Change0%
Ins Owners0.39%
Ins Owner Change0%
Market Cap1.13M
Revenue(TTM)2.88M
Net Income(TTM)-4.44M
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.16 | ||
| P/tB | 0.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)-10.2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS2.69
BVpS6.68
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.28% | ||
| ROE | -62.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.96% | ||
| FCFM | N/A |
ROA(3y)-45.87%
ROA(5y)-39.87%
ROE(3y)-63.58%
ROE(5y)-55.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.89%
GM growth 5Y-0.41%
F-Score4
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7650% | ||
| Cap/Sales | 1.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.72 | ||
| Altman-Z | -5.21 |
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1192.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-591.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-10.69%
Revenue growth 5Y-11.19%
Sales Q2Q%13.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-45.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.36%
OCF growth 3YN/A
OCF growth 5YN/A
SCWORX CORP / WORX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SCWORX CORP (WORX) stock?
ChartMill assigns a fundamental rating of 2 / 10 to WORX.
What is the valuation status for WORX stock?
ChartMill assigns a valuation rating of 0 / 10 to SCWORX CORP (WORX). This can be considered as Overvalued.
How profitable is SCWORX CORP (WORX) stock?
SCWORX CORP (WORX) has a profitability rating of 0 / 10.
How financially healthy is SCWORX CORP?
The financial health rating of SCWORX CORP (WORX) is 6 / 10.